Navigation Links
Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
Date:5/10/2011

ng aplastic anemia, have been reported with TNF blockers.  Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with certolizumab pegol.  Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on certolizumab pegol.  Consider discontinuation of certolizumab pegol therapy in patients with confirmed significant hematologic abnormalities.

Drug Interactions

An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with anakinra or abatacept.  Formal drug interaction studies have not been performed with rituximab or natalizumab; however because of the nature of the adverse events seen with these combinations with TNF blocker therapy, similar toxicities may also result from the use of certolizumab pegol in these combinations.  Therefore, the combination of certolizumab pegol with anakinra, abatacept, rituximab, or natalizumab is not recommended.  Interference with certain coagulation assays has been detected in patients treated with certolizumab pegol.  There is no evidence that certolizumab pegol therapy has an effect on in vivo coagulation.  Certolizumab pegol may cause erroneously elevated aPTT assay results in patients without coagulation abnormalities.

Autoimmunity

Treatment with certolizumab pegol may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome.  Discontinue treatment if symptoms of lupus-like syndrome develop.

Immunizations

Do not administer live vaccines or attenuated vaccines concurrently with certolizumab pegol.

Adverse Reactions

In controlled Crohn's cl
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
2. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
3. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
6. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
7. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
8. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
9. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the Morgan ... at 10:20 a.m. ET. The conference will be held ... New York City . About Abaxis ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... ARLINGTON HEIGHTS, Ill., Sept. 12 Even as,many ... available today,we are stopped by our rear reflection and ... study published in the October issue of Plastic and,Reconstructive ... Plastic Surgeons (ASPS), reveals a new back lift procedure ...
... Ala., Sept. 11 - Southern,Research Institute and ... from a study testing Naltrexone-derived,pyridomorphinan (SoRI-9409) will ... of,the journal Biological Psychiatry. The publication is ... suggests that a new compound that,causes selective ...
Cached Medicine Technology:Say 'Goodbye' to Back Fat Rolls 2Novel Compound Shows Promise for Treatment of Alcoholism 2Novel Compound Shows Promise for Treatment of Alcoholism 3Novel Compound Shows Promise for Treatment of Alcoholism 4
(Date:9/2/2014)... Healthcare professionals will be able to access ... available at the point of care following an agreement ... Comprehensive Cancer Network® (NCCN®). Information from NCCN will ... the content available from the clinical reference tool ... of 25 of the world's leading cancer centers devoted ...
(Date:9/2/2014)... from cancer surgery may be influenced by more ... Family conflicts and other non-medical problems may raise ... study has found. Addressing such quality-of-life issues before ... recoveries and save health care dollars, the research ... patients, and found that patients with a poor ...
(Date:9/2/2014)... the key to more youthful immune function might already ... in the Journal of Leukocyte Biology ... old mice had different responses to Mycobacterium tuberculosis ... were reversed by ibuprofen. , "Inflammation in old age ... Turner, Ph.D., a researcher involved in the work from ...
(Date:9/2/2014)... According to a new report by ... authority in medical device market research, the ... grow to over €2 billion in 2020. Growth ... number of procedures for the treatment of BPH, ... TURP devices, laser BPH devices, brachytherapy, urinary catheters, ...
(Date:9/2/2014)... New York (PRWEB) September 02, 2014 ... application of nanotechnology in diagnosing, treating and/or prevention ... are applied for treating cardiovascular, neurological, and oncology ... utilization of knowledge pertaining to various nanoparticles, their ... body., There still exists considerable scope for research ...
Breaking Medicine News(10 mins):Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices worldwide, today announced the company and,its employees ... million,through the Red Cross Society of China to ... Mr. Xu Hang and Mr. Li Xiting,Mindray,s co-chief ...
... alternative,medicine is a diverse group of health care ... traditional medicine. According to the U.S.,Department of Health ... and alternative medicine, which includes dietary supplements., ... of dietary supplements has grown considerably in the ...
... Hopkins undergraduates have designed and built a device to ... their beds and walk while remaining tethered to essential ... whether carefully supervised rehabilitation, as opposed to continuous sedation ... care patients. , Some clinicians believe that allowing ICU ...
... LONDON, May 29 More northern women feel bloating ... of them likely to,experience it at any one time, ... from the West Midlands and Yorkshire and Humberside fared ... experiencing the least,amount of bloated feelings. And 61% of ...
... youth smoking uptake greatly reduced if parents quit, LONDON, ... research shows that a child,s odds of daily smoking are,reduced ... continue,to smoke. And if both parents were smokers but quit, ... shows that mothers who,quit are less likely to have children ...
... The following is a,statement of Matthew L. Myers, ... Sheila Dixon and Baltimore City Health Department,Commissioner Dr. ... protect,the city,s children and health by proposing a ... The proliferation of individually sold cigars in ...
Cached Medicine News:Health News:Mindray Donates Cash and Equipment for Sichuan Earthquake Relief 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 5Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 6Health News:Students' device allows ICU patients to get back on their feet 2Health News:Students' device allows ICU patients to get back on their feet 3Health News:North South Divide Exists in UK Digestive Health 2Health News:North South Divide Exists in UK Digestive Health 3Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 2Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 3Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 4Health News:Baltimore's Proposed Ban on Sale of Single, Cheap Cigars Would Protect Kids and Health 2
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: